Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
53969 participants
OBSERVATIONAL
2017-10-15
2017-11-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Effectiveness and Safety Between Warfarin and Dabigatran
NCT03254134
A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin
NCT05051904
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
NCT04878497
Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan
NCT02631057
Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..
NCT04297150
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients prescribed with Oral Anti-coagulants
warfarin and non-vitamin K dependent oral anti-coagulants
warfarin
warfarin
dabigatran
Non-vitamin K dependent oral anti-coagulants (NOACs)
Apixaban
Non-vitamin K dependent oral anti-coagulants (NOACs)
Edoxaban
Non-vitamin K dependent oral anti-coagulants (NOACs)
Rivaroxaban
Non-vitamin K dependent oral anti-coagulants (NOACs)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
warfarin
warfarin
dabigatran
Non-vitamin K dependent oral anti-coagulants (NOACs)
Apixaban
Non-vitamin K dependent oral anti-coagulants (NOACs)
Edoxaban
Non-vitamin K dependent oral anti-coagulants (NOACs)
Rivaroxaban
Non-vitamin K dependent oral anti-coagulants (NOACs)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prescribed dabigatran, rivaroxaban, apixaban, edoxaban or warfarin
* Patients with confirmed date of initiation of OACs
* Patients with a minimum of 6 months of enrolment data prior to index date
* Has an index date between 14th of March 2011 to 30 June, 2016
Exclusion Criteria
* Patients with prescriptions of index treatment in the 6 months prior to index date
* Patients without enrolment period of at least six month in the database
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yasaka M, Yokota H, Suzuki M, Yamane T, Ono Y. Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy. Cardiol Ther. 2020 Jun;9(1):189-199. doi: 10.1007/s40119-020-00171-w. Epub 2020 May 11.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1321-0022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.